TNFSF13B and myasthenia gravis: To further establish a causal relationship between BAFF and MG pathogenesis, we employed an EAMG model treated with an anti‐BAFF monoclonal antibody (2 mg kg−1 day−1, intraperitoneally, twice weekly; Figure S12C, Supporting Information).